dc.contributor.author |
Nurulain S |
|
dc.contributor.author |
Kalász Huba |
|
dc.contributor.author |
Szegi Péter |
|
dc.contributor.author |
Kuca K |
|
dc.contributor.author |
Adem A |
|
dc.contributor.author |
FARZAD HASHEMI |
|
dc.contributor.author |
Tekes Kornélia |
|
dc.date.accessioned |
2014-09-04T21:15:35Z |
|
dc.date.available |
2014-09-04T21:15:35Z |
|
dc.date.issued |
2013 |
|
dc.identifier |
84885923496 |
|
dc.identifier.citation |
pagination=703-710;
journalVolume=25;
journalIssueNumber=4;
journalTitle=ACTA CHROMATOGRAPHICA; |
|
dc.identifier.uri |
http://repo.lib.semmelweis.hu//handle/123456789/386 |
|
dc.identifier.uri |
doi:10.1556/AChrom.25.2013.4.8 |
|
dc.description.abstract |
HPLC monitoring of pharmacokinetics was done in two body compartments of rats following intramuscular treatments with three different doses of K027, a bispyridinium mono-aldoxime type of antidotes to organoposphate intoxicated subjects. Reversed-phase HPLC separation with electrochemical detections was done to monitor the onset, the maximum level, and offset in K027 concentration. Serum level of K027 showed a fast onset, independently from the doses of K027. Drug level in brain was showing an essentially delayed kinetics. |
|
dc.relation.ispartof |
urn:issn:1233-2356 |
|
dc.title |
HPLC analysis in drug level monitoring of K027 |
|
dc.type |
Journal Article |
|
dc.date.updated |
2014-09-04T13:50:04Z |
|
dc.language.rfc3066 |
en |
|
dc.identifier.mtmt |
2484113 |
|
dc.identifier.wos |
000325291400008 |
|
dc.contributor.department |
SE/GYTK/Gyógyszerhatástani Intézet |
|
dc.contributor.institution |
Semmelweis Egyetem |
|